قارن الطرق
راجع الطرق التي اخترتها جنبًا إلى جنب؛ الصفوف المختلفة مميَّزة.
| مقياس ميلانكوليا لجودة الحياة (MelasQoL)× | مقياس POEM (مقياس الأكزيما الموجه للمريض)× | |
|---|---|---|
| المجال | الأمراض الجلدية | الأمراض الجلدية |
| العائلة | Process / pipeline | Process / pipeline |
| سنة النشأة≠ | 2006 | 2004 |
| صاحب الطريقة≠ | Cestari TF, Hexsel D | Charman CR, Venn AJ, Williams HC |
| النوع | Self-report | Self-report |
| المصدر التأسيسي≠ | Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. link ↗ | Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519. DOI ↗ |
| الأسماء البديلة | Melasma-QoL | POEM Score |
| ذات صلة≠ | 3 | 2 |
| الملخص≠ | MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes. | The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care. |
| ScholarGateمجموعة البيانات ↗ |
|
|